CEO SUMMARY: Evidence is accumulating that tissue banking may be where the “rubber meets the road;” where pharma money funds technology enhancements that directly benefit the profession of pathology. Without question, the need by pharma, biotech, and genomic companies to access, analyze and understand the tissue of targeted subpopulations is creating an opportunity for savvy
Tag: the future of pathology
CEO SUMMARY: Hospital-based pathologists are increasingly the target of buy-out offers by the emerging group of pathology based physician practice management (PPM) companies. But MedPartners decided that managing hospital-based physicians was something that was not in its best interest. What message should pathologists read into MedPartner’s exit from managing hospital-based doctors?
PATHOLOGISTS MAY WANT TO PAY